Bas W.G. van Rhijn - Concepedia

Author

Bas W.G. van Rhijn

Also Known As

B W van Rhijn, B. W. G. van Rhijn, B.W.G. Van Rhijn, B.W.G. van Rhijn, Bas W G. van Rhijn, Bas W. G. Van Rhijn, Bas W. G. van Rhijn, Bas W.G. Van Rhijn, Bas W.G. van Rhijn, BasVan Rhijn

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute University of Regensburg University of British Columbia Leiden University Medical Center

About

Bas W.G. van Rhijn is an author at The Netherlands Cancer Institute specializing in urology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	905
2	Surgical Oncology	6	6	731
3	Pathology	4	4	472
4	Health Sciences	2	2	139
5	Cancer Cell Biology	1	1	309

Bas W.G. van Rhijn

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Bas W.G. van Rhijn, Irene Lurkin, François Radvanyi, PubMed Tumor BiologySurgical OncologyUrologyTumoral PathologyGenitourinary Cancer	2001	309
Penile Sparing Surgery for Penile Cancer—Does it Affect Survival? Rosa S. Djajadiningrat, Erik van Werkhoven, Wim Meinhardt, The Journal of Urology UrologySurgical OncologyGenitourinary CancerMedicineCancer Management	2013	137
Sarcopenia as a comorbidity‐independent predictor of survival following radical cystectomy for bladder cancer Roman Mayr, Michael Gierth, Florian Zeman, Journal of Cachexia Sarcopenia and Muscle Radical CystectomySurgical OncologyCancer ManagementPrognosisMultimodality	2018	128
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis Joep J. de Jong, Yang Liu, A. Gordon Robertson, Genome Medicine	2019	89
Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer Roman Mayr, Hans‐Martin Fritsche, Florian Zeman, World Journal of Urology Radical CystectomyUrologySurgical OncologyGenitourinary CancerMedicine	2018	87
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial Jeroen van Dorp, Christodoulos Pipinikas, Britt B.M. Suelmann, Nature Medicine Phase 1BUrologyGenitourinary CancerMedicineClinical Trials	2023	70
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial Hielke M. de Vries, Tynisha S. Rafael, Alberto Gil-Jimenez, Journal of Clinical Oncology	2023	61
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment Damien Pouessel, Y. Neuzillet, Laura S. Mertens, Annals of Oncology UrologySurgical OncologyGenitourinary CancerTumor HeterogeneityMedicine	2016	59
<scp>P</scp>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas Henning Reis, Kristan E. van der Vos, Christian Niedworok, International Journal of Cancer UrologyGenitourinary CancerMedicineHistopathologyPathology	2018	59
Value of tissue markers p27<sup>kip1</sup>, MIB‐1, and CD44s for the pre‐operative prediction of tumour features in screen‐detected prostate cancer André N. Vis, Bas W.G. van Rhijn, Marinus A. Noordzij, The Journal of Pathology	2002	46

Page 1